Efficacy of Camrelizumab in the Treatment of Elderly Patients With Non-Small Cell Lung Cancer
Objective To analyze the effect of camrelizumab on clinical efficacy,adverse reactions and immune function in elderly patients with non-small cell lung cancer receiving gemcitabine and cisplatin chemotherapy.Methods A total of 76 elderly patients with non-small cell lung cancer admitted to the department of respiratory medicine,Wuyishan Municipal Hospital from January 2018 to October 2023 were selected as the study objects.They were divided into control group(n=38)and study group(n=38)according to different treatment methods.The control group was treated with gemcitabine and cisplatin chemotherapy,while the study group was treated with camrelizumab on the basis of gemcitabine and cisplatin chemotherapy.The therapeutic effects of the two groups were observed and analyzed,and the changes of immune function and tumor markers were compared,and the adverse reactions were statistically compared.Results The total effective rate of the study group was 68.42%,which was higher than 42.11%of the control group,and the difference was statistically significant(P<0.05).After treatment,carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and cytokeratin-19 fragment 21-1(CYFRA21-1)levels of the study group were(24.88±5.76)ng/mL,(64.48±8.11)U/mL and(2.68±0.75)μg/L,respectively,which were lower than(30.11±7.18)ng/mL,(70.31±10.26)U/mL,(3.39±1.31)μg/L of the control group,and the differences were statistically significant(P<0.05).The CD4+and CD4+/CD8+in the study group were(42.31±5.58)%and(1.73±0.21),respectively,which were higher than(34.46±5.69)%and(1.26±0.22)in the control group,the CD8+in the study group was(24.22±3.01)%,which was lower than(27.11±3.11)%in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of non-small cell lung cancer patients receiving gemcitabine and cisplatin chemotherapy,combined application of camrelizumab can significantly improve the short-term efficacy,reduce the levels of tumor markers,and improve the cellular immune function,and not increase the adverse reactions,with high safety.
camrelizumabgemcitabinecisplatinchemotherapy regimenelderlynon-small cell lung cancer
万方数据
维普
